Navigation Links
SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study
Date:7/7/2010

Novo Nordisk was ranked by endocrinologists as the top company overall in a recent SDI study. Novo Nordisk increased sales calls to endocrinologists 30%.

(Vocus) July 7, 2010 -- According to SDI’s Pharmaceutical Company Image 2010 study, Novo Nordisk was ranked by endocrinologists as the top company overall. The company was mentioned by 62% of the endocrinologists who participated in the annual study – a substantial increase from last year, when it was mentioned by 52% of participants and ranked second.

Eli Lilly, ranked first by this specialty group in 2009, finished second this year even though its percentage of mentions was similar both years at 52% and 53%, respectively. Sanofi-aventis U.S. was ranked third.

During the 12 months ending April 2010, Lilly representatives made the most sales calls to endocrinologists, accounting for 12% of all calls to this specialty group, followed by Novo Nordisk, which accounted for 10%. The volume of calls made by each company increased from the previous 12 months, with Lilly's rising by 17% and Novo Nordisk’s by 30%.

When Novo representatives called on endocrinologists, the products they discussed most often were Levemir; Victoza which was launched in February 2010; and NovoLog.

SDI’s Company Image 2010, a comprehensive analysis of pharmaceutical company and industry image as perceived by key healthcare audiences, surveyed over 9,000 participants in March and April 2010, including physicians from 27 specialties, nurse practitioners, physician assistants, pharmacists, medical directors, pharmacy executives, and consumers, regarding their opinions of the pharmaceutical industry and industry trends.

The 2010 version represents the 11th edition of this landmark study that enables market researchers and brand management to:

 
  • Evaluate a company's overall image relative to market success and increases in prescribing.
  • Validate corporate initiatives to promote overall company image.
  • Understand the importance of company attributes among key customer groups.
  • Identify whether direct-to-consumer advertising drives consumer perceptions of pharmaceutical manufacturers.

About SDI

SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, retail pharmacy, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world’s top 50 pharmaceutical and biotech firms as its clients.

###

Read the full story at http://www.prweb.com/releases/2010/SDICompanyImage/prweb4219854.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. CNBC Presents 'Tom Brokaw Reports: BOOMER$!' on Thursday, March 4th at 9PM ET/PT
2. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
3. SDI Reports: Emergency Room Visits Covered by Medicaid Increased 6% in 2009
4. SDI Reports: Hospital Outpatient Surgical Procedures Increasing, Surgery Centers Growing
5. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
6. SDI Reports: Roughly Half of Patients Prescribed the Most Popular Osteoporosis Drugs Discontinue Therapy Within 6 Months -- Amgen's Prolia Offers New Dosing Option
7. Charlie Kimball Secures Partnership with Novo Nordisk, Maker of the Levemir FlexPen, for 2010 Firestone Indy Lights Campaign
8. Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights
9. AntiBiggestLoser.com; New Blog Takes Aim at Worldwide Reality TV Show, "The Biggest Loser"
10. USA's Greatest Speed Skater Takes His Medical Practice to the Cutting Edge
11. Global Nutrition Firm Takes Dose of SonicWALL to Boost Network Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology: